跳至主要内容
临床试验/NCT05937347
NCT05937347已完成不适用

Mindfulness and Cognitive Training Programs for Children with Attention Deficit Hyperactivity Disorder (ADHD): a Randomized, Controlled Trial (the NeuroMind Study)

Fundació Sant Joan de Déu2 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2023年7月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
122
试验地点
2
主要终点
ADHD symptoms (inattention, hyperactivity, impulsivity)

研究概览

简要总结

The present project will evaluate through a Randomized Controlled Trial (RCT) with 5-month follow-up, the efficacy (5-month time horizon), adjunctive to TAU, of three 8-week interventions: a) the Mindfulness for Health program (i. e., M4H), b) a Cognitive Training (CT) program through NeuronUp platform and a program combining both (Mindfulness and Cognitive Training program, i. e., UP4H), a, as compared to TAU, in children (7-12 years old) with ADHD. In order to evaluate stability of clinical changes and to determine the mechanisms of action of the interventions studied, pre-post changes and at 5-months followup after the start of treatment will be evaluated in ADHD symptoms (inattention, hyperactivity, impulsivity), general functioning, clinical global impression, executive functions (verbal fluency, working memory, cognitive flexibility, inhibition), and comorbid symptoms (disruptive behavior, anxiety and depression) along with mindfulness skills. In the field of personalized treatment in ADHD, the design of the present study will also make it possible to establish whether certain baseline psychosocial and clinical characteristics may be associated with short- and medium-term clinical response to each of the treatments studied.

详细描述

Introduction

The NeuroMind study is aimed at assessing the efficacy of 3 interventions based on Mindfulness and/or Cognitive Training programs: a Mindfulness and Cognitive Training program (i. e., UP4H), a Mindfulness program (i. e., M4H) and a Cognitive Training program (i. e. CT). This study will evaluate the short- and mid-time efficacy of these 3 interventions for the first time in children with ADHD. The objectives of this 5-month RCT, are (i) to examine the efficacy of adding UP4H, M4H or CT to treatment-as-usual (TAU) for children (7-12 years old) with ADHD; (ii) to identify pre-post differences in ADHD symptoms (inattention, hyperactivity, impulsivity), in executive functions (verbal fluency, working memory, cognitive flexibility, inhibition), and in comorbid symptoms (disruptive behavior, anxiety and depression) in the four study arms and (iii) to analyze the role of the mindful attention awareness as a psychological process variable mediator of 5-month clinical outcomes. Methods and analysis: Participants will be 120 children with ADHD (7-12 years old) recruited at CSMIJ Sant Joan de Déu Terres de Lleida (Lleida, Spain), randomly allocated to one of the four study arms: TAU vs TAU+CT vs TAU+M4H vs TAU+UP4H. A comprehensive assessment to collect ADHD symptoms (inattention, hyperactivity, impulsivity), executive functions (verbal fluency, working memory, cognitive flexibility, inhibition), comorbid symptoms (disruptive behavior, anxiety and depression), mindful attention awareness, general functioning and clinical global impression will be conducted pre-intervention, post-intervention (8 weeks), and at 5-month follow-up. Linear mixed-effects model analyses, mediation analysis and sensitivity analyses will be conducted on the basis of intention-to-treat approach and according to whether the patients are completers, or whether they completed the majority of the sessions (75% attendance).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
7 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children of both sexes, between 7 and 12 years of age.
  • Diagnosis of ADHD according to the DSM-5 criteria by a specialist and confirmed by the Kiddie-Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version (K-SADS-PL).
  • ADHD medication dose is stable in the last 2 months or there is an informed decision on not taking ADHD medication.
  • Children and parents have an adequate mastery of the Spanish language.
  • Children and parents are available to meet all visits.
  • Children's representatives (either parents or legal guardians) must understand the conditions of the study and sign the informed consent.
  • Psychiatric comorbidities are allowed except psychosis, bipolar illness, active suicidality, untreated posttraumatic stress disorder or substance use (checked by the structured interview K-SADS-PL) , provided ADHD is the primary diagnosis in the child.
  • Children have an IQ ≥ 80 checked by the Kaufman Brief Intelligence Test (K-BIT).

排除标准

  • Diagnosis of Autism Spectrum Disorder (ASD) according to the DSM-5 criteria by a specialist or confirmed by the Social Communication Questionnaire (SCQ).
  • Children who received psychological or psycho-educational treatment in the last 2 months or whose parents don't agree not to seek it during the study.
  • Children have participated in a mindfulness programme in the past or the current year
  • Children are participating in another clinical trial.

结局指标

主要结局

ADHD symptoms (inattention, hyperactivity, impulsivity)

时间窗: Change from baseline values at 5 months

Conners' Parent Rating Scale-Revised (CPRS-R) Short form

次要结局

  • Executive functions (verbal fluency, working memory, cognitive flexibility, inhibition)(Change from baseline values at 5 months)
  • Disruptive behavior, anxiety and depression(Change from baseline values at 5 months)
  • Clinical Global Impression(Change from baseline values at 5 months)
  • Mindful attention awareness(Change from baseline values at 5 months)
  • General functioning(Change from baseline values at 5 months)
  • Anxiety(Change from baseline values at 5 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验